Evidence map›Paper›PMID 37019372›Full record

ArticleThe American journal of medicine2023

Renin-Angiotensin Inhibition and Outcomes in HFrEF and Advanced Kidney Disease.

Samir Patel, Phillip H Lam, Evangelos I Kanonidis, Amiya A Ahmed, Venkatesh K Raman, Wen-Chih Wu, Patrick Rossignol, Cherinne Arundel, Charles Faselis, Ioannis E Kanonidis and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The American journal of medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Samir PatelVeterans Affairs Medical Center, Washington, DC; George Washington University, Washington, DC.
Phillip H LamVeterans Affairs Medical Center, Washington, DC; Georgetown University, Washington, DC; MedStar Washington Hospital Center, Washington, DC.
Evangelos I KanonidisDemocritus University of Thrace, Alexandroupoli, Greece.
Amiya A AhmedUniversity of Maryland, Baltimore; Yale University, New Haven, Conn.
Venkatesh K RamanVeterans Affairs Medical Center, Washington, DC; Georgetown University, Washington, DC.
Wen-Chih WuVeterans Affairs Medical Center, Providence, RI; Brown University, Providence, RI.
Patrick RossignolUniversity of Lorraine, Nancy, France and Princess Grace Hospital, Monaco.
Cherinne ArundelVeterans Affairs Medical Center, Washington, DC; George Washington University, Washington, DC; Georgetown University, Washington, DC.
Charles FaselisVeterans Affairs Medical Center, Washington, DC; George Washington University, Washington, DC; Uniformed Services University, Washington, DC.
Ioannis E KanonidisAristotle University, Thessaloniki, Greece.
Prakash DeedwaniaVeterans Affairs Medical Center, Washington, DC; University of California, San Francisco.
Richard M AllmanGeorge Washington University, Washington, DC; University of Alabama at Birmingham.
Farooq H SheikhGeorgetown University, Washington, DC; MedStar Washington Hospital Center, Washington, DC.
Gregg C FonarowUniversity of California, Los Angeles.
Bertram PittUniversity of Michigan, Ann Arbor.
Ali AhmedVeterans Affairs Medical Center, Washington, DC; George Washington University, Washington, DC; Georgetown University, Washington, DC. Electronic address: ali.ahmed@va.gov.

Funding

Heart failure, chronic kidney disease, and renin-angiotensin system inhibitionR01HL085561 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI AHMED, ALI · 2006 to 2009
$1.5M
Neurohormonal Blockade and Outcomes in Diastolic Heart FailureR01HL097047 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI AHMED, ALI · 2009 to 2010
$915k
Improving Outcomes in Veterans with Heart Failure and Chronic Kidney DiseaseI01HX002422 · VA · U.S. DEPT/VETS AFFAIRS MEDICAL CENTER · PI AHMED, ALI, WU, WEN-CHIH · 2019 to 2025
–
HSRD VA I01 HX002422NHLBI NIH HHS R01 HL085561NHLBI NIH HHS R01 HL097047
6 · The paper itself

Abstract

backgroundRenin-angiotensin system inhibitors improve outcomes in patients with heart failure with reduced ejection fraction (HFrEF). However, less is known about their effectiveness in patients with HFrEF and advanced kidney disease.

methodsIn the Medicare-linked Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF), 1582 patients with HFrEF (ejection fraction ≤40%) had advanced kidney disease (estimated glomerular filtration rate <30 mL/min/1.73 m

resultsThe combined endpoint of heart failure readmission or all-cause mortality occurred in 79% and 84% of patients initiated and not initiated on ACE inhibitors or ARBs, respectively (HR associated with initiation, 0.79; 95% CI, 0.63-0.98). Respective HRs (95% CI) for the individual endpoints of - Respective HRs (95% CI) for the individual endpoints of all-cause mortality and heart failure readmission were 0.81 (0.63-1.03) and 0.63 (0.47-0.85).

conclusionsThe findings from our study add new information to the body of cumulative evidence that suggest that renin-angiotensin system inhibitors may improve clinical outcomes in patients with HFrEF and advanced kidney disease. These hypothesis-generating findings need to be replicated in contemporary patients.

Indexed as

Heart FailureKidney DiseasesAgedAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAngiotensinsFemaleHumansMaleMedicareReninStroke VolumeUnited StatesAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAngiotensinsReninAdvanced kidney diseaseHeart failureHospitalizationMortalityRenin-angiotensin system inhibitors

Identifiers

PMID37019372
PMCPMC10466279

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.